Literature DB >> 28272780

Microfluidic Encapsulation of Prickly Zinc-Doped Copper Oxide Nanoparticles with VD1142 Modified Spermine Acetalated Dextran for Efficient Cancer Therapy.

Hongbo Zhang1,2, Dongfei Liu1, Liang Wang3, Zehua Liu1, Runrun Wu4, Agne Janoniene5, Ming Ma6, Guoqing Pan7, Lina Baranauskiene5, Linlin Zhang6, Wenguo Cui7, Vilma Petrikaite5,8, Daumantas Matulis5, Hongxia Zhao3, Jianming Pan4,9, Hélder A Santos1.   

Abstract

Structural features of nanoparticles have recently been explored for different types of applications. To explore specific particles as nanomedicine and physically destroy cancer is interesting, which might avoid many obstacles in cancer treatment, for example, drug resistance. However, one key element and technical challenge of those systems is to selectively target them to cancer cells. As a proof-of-concept, Prickly zinc-doped copper oxide (Zn-CuO) nanoparticles (Prickly NPs) have been synthesized, and subsequently encapsulated in a pH-responsive polymer; and the surface has been modified with a novel synthesized ligand, 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl] benzenesulfonamide (VD1142). The Prickly NPs exhibit very effective cancer cell antiproliferative capability. Moreover, the polymer encapsulation shields the Prickly NPs from unspecific nanopiercing and, most importantly, VD1142 endows the engineered NPs to specifically target to the carbonic anhydrase IX, a transmembrane protein overexpressed in a wide variety of cancer tumors. Intracellularly, the Prickly NPs disintegrate into small pieces that upon endosomal escape cause severe damage to the endoplasmic reticulum and mitochondria of the cells. The engineered Prickly NP is promising in efficient and targeted cancer treatment and it opens new avenue in nanomedication.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Zn-doped CuO; acetalated dextran; microfluidic; mitochondria; targeted cancer therapy

Mesh:

Substances:

Year:  2017        PMID: 28272780     DOI: 10.1002/adhm.201601406

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  5 in total

Review 1.  Recent advances of controlled drug delivery using microfluidic platforms.

Authors:  Sharma T Sanjay; Wan Zhou; Maowei Dou; Hamed Tavakoli; Lei Ma; Feng Xu; XiuJun Li
Journal:  Adv Drug Deliv Rev       Date:  2017-09-15       Impact factor: 15.470

2.  Responsive Inverse Opal Scaffolds with Biomimetic Enrichment Capability for Cell Culture.

Authors:  Changmin Shao; Yuxiao Liu; Junjie Chi; Jie Wang; Ze Zhao; Yuanjin Zhao
Journal:  Research (Wash D C)       Date:  2019-10-29

3.  Inhibition of Carbonic Anhydrase IX Suppresses Breast Cancer Cell Motility at the Single-Cell Level.

Authors:  Agne Janoniene; Linas Mazutis; Daumantas Matulis; Vilma Petrikaite
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

4.  Helper T Cell (CD4+) Targeted Tacrolimus Delivery Mediates Precise Suppression of Allogeneic Humoral Immunity.

Authors:  Jia Shen; Chang Liu; Pengpeng Yan; Meifang Wang; Luying Guo; Shuaihui Liu; Jianghua Chen; Jessica M Rosenholm; Hongfeng Huang; Rending Wang; Hongbo Zhang
Journal:  Research (Wash D C)       Date:  2022-07-16

5.  Microfluidic-Assisted Fabrication of Dual-Coated pH-Sensitive Mesoporous Silica Nanoparticles for Protein Delivery.

Authors:  Berrin Küçüktürkmen; Wali Inam; Fadak Howaili; Mariam Gouda; Neeraj Prabhakar; Hongbo Zhang; Jessica M Rosenholm
Journal:  Biosensors (Basel)       Date:  2022-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.